IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: As depicted in Figure 10, a higher IL-6-stained area (40.4%) was observed in the CML-injected group that was significantly 9.0-fold (p < 0.001) higher than the IL-6-stained area quantified in the control (4.5%), suggesting the impact of CML on the IL-6 production.